US Vasomotor Symptoms Market

ID: MRFR/HC/18538-HCR

100 Pages

Rahul Gotadki

October 2025

US Vasomotor Symptoms Market Research Report By Therapy Type (Hormonal, Non-Hormonal) and By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Stores) - Forecast to 2035

US Vasomotor Symptoms Market Infographic

Single User

Multiple License

Enterprise User

Summary Table of Contents Segmentation Download PDF

1. Market Overview

2. Market Trends

3. Market Segment Insights

4. Key Players and Competitive Insights

5. Industry Developments

6. Market Segmentation

7. Report Scope

8. Market Highlights

9. FAQs

Certified Researchers

Customize Report

US Vasomotor Symptoms Market Summary

The United States Vasomotor Symptoms market is projected to grow significantly from 844.2 million USD in 2024 to 1824.2 million USD by 2035.

Key Market Trends & Highlights

US Vasomotor Symptoms Key Trends and Highlights

The market valuation is expected to reach 1824.2 million USD by 2035, indicating substantial growth.
A compound annual growth rate of 7.26 percent is anticipated from 2025 to 2035, reflecting increasing demand.
In 2024, the market is valued at 844.2 million USD, showcasing its current economic footprint.
Growing adoption of innovative treatment options due to rising awareness of vasomotor symptoms is a major market driver.

US Vasomotor Symptoms Market

CAGR

7.26%

Market Size & Forecast

2024 Market Size	844.2 (USD Million)
2035 Market Size	1824.2 (USD Million)
CAGR (2025-2035)	7.26%

Major Players

Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Eli Lilly, HoffmannLa Roche, Horizon Therapeutics, Pfizer, Amgen, AbbVie, Sanofi, Johnson and Johnson, GSK, Mylan, Teva Pharmaceuticals

US Vasomotor Symptoms Market Trends

The US Vasomotor Symptoms Market is experiencing a notable shift as awareness around menopause and its associated symptoms increases. With more focus on women's health issues, particularly following research and advocacy campaigns, there is a growing recognition of vasomotor symptoms, such as hot flashes and night sweats, which affect a significant portion of the female population nearing or experiencing menopause. This has driven demand for effective treatment options, which has prompted pharmaceutical companies to research and develop both hormone replacement therapies and non-hormonal alternatives to target these symptoms.

In recent times, there has also been a rise in preference for holistic and natural remedies, reflecting a broader trend in health and wellness. Many women are seeking non-invasive treatments such as herbal supplements, lifestyle changes, and alternative therapies, which provides an opportunity for companies to diversify their product lines to meet these preferences. Additionally, telehealth services are gaining traction, allowing women to consult healthcare providers from the comfort of their homes. This trend has been accelerated by the COVID-19 pandemic, underlining the need for accessible healthcare solutions in the US.

Market Segment Insights

Vasomotor Symptoms Market Therapy Type Insights

The US Vasomotor Symptoms Market is experiencing notable growth, driven by the increasing prevalence of symptoms associated with hormonal changes, particularly during menopause. In this context, the Therapy Type segment is principally divided into two critical categories Hormonal and Non-Hormonal therapies. Hormonal therapies, which primarily involve the administration of estrogen, play a significant role in alleviating vasomotor symptoms such as hot flashes and night sweats.

These therapies are often considered the first line of treatment due to their efficacy in managing symptoms effectively. However, there are also concerns regarding the long-term safety and side effects associated with hormonal treatments, which opens up a growing market for Non-Hormonal therapies. Non-Hormonal alternatives, including selective serotonin reuptake inhibitors (SSRIs) and other medications, provide patients with viable options who may be at risk of adverse effects from hormone therapy or who prefer to abstain from hormonal treatments altogether.

This dynamic creates a diversified approach to treatment within the market. With new research and developments continually emerging, the adoption rate of both Therapy Types is influenced by patient preferences and clinical recommendations. The rising awareness of menopause and its associated symptoms has led to increased demand for effective treatment options, resulting in a robust growth in the US Vasomotor Symptoms Market.

Moreover, this segment benefits from an emphasis on personalized medicine, allowing for tailored treatment regimens based on individual patient needs and medical history. The integration of technology, such as telehealth services, further enhances patient access to treatments, making it easier to obtain necessary prescriptions or consultations. As a result, both Hormonal and Non-Hormonal therapies are crucial in addressing the needs of women experiencing vasomotor symptoms, ensuring a comprehensive approach to management and treatment in a rapidly evolving market landscape.

Source: Primary Research, Secondary Research, Market Research Future Database and Analyst Review

Vasomotor Symptoms Market Distribution Channel Insights

The Distribution Channel segment of the US Vasomotor Symptoms Market is crucial, encompassing various avenues through which products reach consumers. Hospital pharmacies play a significant role in ensuring that patients undergoing treatment for vasomotor symptoms receive medications quickly and efficiently, serving as a vital touchpoint for prescription management.

Retail pharmacies provide convenience and accessibility to the general public, often being the first point of contact for patients seeking relief from symptoms associated with menopause. The rise of online stores is transforming the marketplace, catering to the growing trend of e-commerce where patients can discreetly acquire products from the comfort of their homes.

This shift towards online purchasing is driven by increased internet penetration and the growing preference for convenience among consumers. Overall, each distribution channel holds distinct importance in the US Vasomotor Symptoms Market, contributing to a balanced and comprehensive approach that enhances product availability and patient access, aligning with broader trends in the healthcare industry towards improved patient-centric service delivery.

Get more detailed insights about US Vasomotor Symptoms Market

Request Free Sample

Key Players and Competitive Insights

The competitive landscape of the US Vasomotor Symptoms Market is characterized by a dynamic interplay of innovation, strategic alliances, and market expansion efforts by key players. This market segment, primarily driven by the demand for effective treatments for symptoms associated with menopause, has attracted significant attention from pharmaceutical companies looking to enhance their product offerings.

The presence of well-established organizations alongside emerging companies has led to a diverse range of therapies being developed to address the variegated needs of patients experiencing vasomotor symptoms. Analysis of this competitive environment reveals trends in product development, regulatory approvals, and market penetration strategies that are shaping the evolution of the sector in the United States.

Key Companies in the US Vasomotor Symptoms Market market include

Industry Developments

The US Vasomotor Symptoms Market has seen significant recent activity, particularly regarding advancements and partnerships among leading pharmaceutical companies. Bristol Myers Squibb, AstraZeneca, Novartis, and others are noted for their ongoing Research and Development efforts, targeting innovative treatments for menopausal symptoms.

In August 2023, Merck announced a strategic collaboration with Horizon Therapeutics, focusing on an emerging treatment that aims to alleviate vasomotor symptoms associated with menopause. Additionally, Eli Lilly has expanded its product portfolio with a new formulation aimed at reducing hot flashes, securing a competitive edge in the market.

There have also been reports of industry growth, driven by increased awareness and diagnosis of vasomotor symptoms, with the market valuation expected to exceed $4 billion by 2025. Significant occurrences from the past few years include Sanofi's acquisition of a portfolio from another pharmaceutical company in May 2022, enhancing its position in this niche therapeutic area.

The ongoing regulatory support from the Food and Drug Administration encourages innovation, prompting companies like Pfizer and Amgen to invest further in the landscape. Overall, the market shows robust potential, influenced by strong corporate investments and increasing patient demand.

Market Segmentation

Vasomotor Symptoms Market Therapy Type Outlook

Hormonal
Non-Hormonal

Vasomotor Symptoms Market Distribution Channel Outlook

Hospital Pharmacies
Retail Pharmacies
Online Stores

Report Scope

Report Attribute/Metric Source:	Details
MARKET SIZE 2018	789.6(USD Million)
MARKET SIZE 2024	844.2(USD Million)
MARKET SIZE 2035	1824.2(USD Million)
COMPOUND ANNUAL GROWTH RATE (CAGR)	7.256% (2025 - 2035)
REPORT COVERAGE	Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR	2024
MARKET FORECAST PERIOD	2025 - 2035
HISTORICAL DATA	2019 - 2024
MARKET FORECAST UNITS	USD Million
KEY COMPANIES PROFILED	Bristol Myers Squibb, AstraZeneca, Novartis, Merck, Eli Lilly, HoffmannLa Roche, Horizon Therapeutics, Pfizer, Amgen, AbbVie, Sanofi, Johnson and Johnson, GSK, Mylan, Teva Pharmaceuticals
SEGMENTS COVERED	Therapy Type, Distribution Channel
KEY MARKET OPPORTUNITIES	Telehealth vasomotor management programs, Hormone therapy innovations, Non-hormonal treatment advancements, Personalized medicine approaches, Increased awareness and education efforts
KEY MARKET DYNAMICS	increasing menopausal population, growing awareness and education, emergence of novel therapies, expanding telehealth services, rising demand for personalized treatment
COUNTRIES COVERED	US

FAQs

What is the expected market size of the US Vasomotor Symptoms Market in 2024?

The US Vasomotor Symptoms Market is expected to be valued at 844.2 million USD in 2024.

How much is the US Vasomotor Symptoms Market projected to grow by 2035?

By 2035, the market is projected to reach a value of 1824.2 million USD.

What is the expected CAGR for the US Vasomotor Symptoms Market from 2025 to 2035?

The expected CAGR for the US Vasomotor Symptoms Market from 2025 to 2035 is 7.256%.

What are the two main therapy types in the US Vasomotor Symptoms Market?

The two main therapy types in the US Vasomotor Symptoms Market are Hormonal and Non-Hormonal.

What is the market size for Hormonal therapy in the US Vasomotor Symptoms Market in 2024?

The market size for Hormonal therapy is valued at 400.0 million USD in 2024.

What will the market size for Non-Hormonal therapy be in 2035?

The market size for Non-Hormonal therapy is expected to be 944.2 million USD by 2035.

Which companies are the key players in the US Vasomotor Symptoms Market?

Key players in the US Vasomotor Symptoms Market include Bristol Myers Squibb, AstraZeneca, Novartis, and Merck.

What is the growth opportunity within the US Vasomotor Symptoms Market?

The market presents significant growth opportunities driven by increasing awareness and treatment options for vasomotor symptoms.

How will the US Vasomotor Symptoms Market be impacted by emerging trends?

Emerging trends in personalized medicine and non-hormonal treatment options are expected to influence the market positively.

What are the challenges facing the US Vasomotor Symptoms Market?

Challenges include regulatory hurdles and competition among the major pharmaceutical companies.

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Chemicals and Materials

Global Magnesium Sulfate Market – Forecast till 2027